Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Thiamine Against Chronic Rheumatoid Arthritis Fatigue Ended

2022-500922-13-00 Rheumatoid Arthritis 10 2023-02-16
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 New onset type I diabetes 4 2023-01-27
Quercus ilex and Quercus robur allergen extracts. Determination of in the vivo histamine equivalent prick test units (HEP). Ended

2024-515189-14-00 Allergy to Quercus ilex and Quercus robur 4 2023-01-26
Study to Evaluate Safety, Tolerability and Efficacy in patients with Primary Biliary Cholangitis of Saroglitazar Magnesium-III (EPICS-III). Ended

2024-518718-14-00 Primary Biliary Cholangitis (PBC) 10 2023-01-23
Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended

2022-500599-79-00 Mycosis Fungoides 4 2023-01-10
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Thera… Ended

2022-501058-12-00 Giant cell arteritis 4 2022-11-23
A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease Ended

2024-511115-25-00 chronic pulmonary sarcoidosis 4 2022-11-21
MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial Ended

2024-513651-32-00 Juvenile Dermatomyositis 4 2022-11-10
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 5 2022-11-03
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Partici… Ended

2023-509188-26-00 Systemic Lupus Erythematosus (SLE) 3 2022-10-27
ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, d… Ended

2024-516770-29-00 Sjogren's disease 4 2022-10-09
Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511069-12-00 Sjögren’s Syndrome 5 2022-07-28
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships with Clinical Assessments Ended

2023-508957-24-00 Sjögren's syndrome 4 2022-07-27
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Ended

2024-516743-34-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 3 2022-07-25
Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination after a local application of cream, called IMIQUIMOD, in cirrhotic patients… Ended

2024-514605-61-00 Cirrhotic patients who have already received a HBV vacc 4 2022-07-08
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero… Ended

2022-502981-26-00 Systemic Sclerosis 3 2022-06-27
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patien… Ended

2024-519527-14-00 Allergic rhinoconjunctivitis 5 2022-06-09
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host disease. Ended

2023-507960-38-00 Acute graft versus host disease (aGVHD) 4 2022-06-01
Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic … Ended

2024-513653-75-00 Eosinophilic granulomatosis with polyangiitis (EGPA), f 5 2022-05-30
A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended

2023-508645-40-00 Bullous Pemphigoid (BP) 10 2022-05-10
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-05-09
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult… Ended

2024-515832-59-00 Bullous Pemphigoid 5 2022-05-03